In summary, the regulatory effects of anti-tumor drugs on HIF-1α can affect tumor dormancy and awakening during therapy, and individual differences of HIF-1α need to be considered when chemotherapy drugs were selected. The gene discussed is HIF1A; the disease is neoplasm.